Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial

Marian L. Neuhouser, Jeannette Schenk, Ju Song Yoon, Catherine M. Tangen, Phyllis J. Goodman, Michael Pollak, David F. Penson, Ian M. Thompson, Alan R. Kristal

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

BACKGROUND. We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS. We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was ≥12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS. IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or ≥65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS. A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies.

Original languageEnglish (US)
Pages (from-to)1477-1486
Number of pages10
JournalProstate
Volume68
Issue number13
DOIs
StatePublished - Sep 15 2008

Fingerprint

Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Hyperplasia
Prostate
Prostatic Neoplasms
Odds Ratio
Placebos
Anniversaries and Special Events
Serum
Case-Control Studies
Carrier Proteins
Logistic Models
Cell Proliferation
Apoptosis
Peptides
Therapeutics

Keywords

  • Case-control studies
  • Insulin-like growth factor binding proteins
  • Insulin-like growth factors
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Urology
  • Medicine(all)

Cite this

Neuhouser, M. L., Schenk, J., Yoon, J. S., Tangen, C. M., Goodman, P. J., Pollak, M., ... Kristal, A. R. (2008). Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate, 68(13), 1477-1486. https://doi.org/10.1002/pros.20819

Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. / Neuhouser, Marian L.; Schenk, Jeannette; Yoon, Ju Song; Tangen, Catherine M.; Goodman, Phyllis J.; Pollak, Michael; Penson, David F.; Thompson, Ian M.; Kristal, Alan R.

In: Prostate, Vol. 68, No. 13, 15.09.2008, p. 1477-1486.

Research output: Contribution to journalArticle

Neuhouser, ML, Schenk, J, Yoon, JS, Tangen, CM, Goodman, PJ, Pollak, M, Penson, DF, Thompson, IM & Kristal, AR 2008, 'Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial', Prostate, vol. 68, no. 13, pp. 1477-1486. https://doi.org/10.1002/pros.20819
Neuhouser, Marian L. ; Schenk, Jeannette ; Yoon, Ju Song ; Tangen, Catherine M. ; Goodman, Phyllis J. ; Pollak, Michael ; Penson, David F. ; Thompson, Ian M. ; Kristal, Alan R. / Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. In: Prostate. 2008 ; Vol. 68, No. 13. pp. 1477-1486.
@article{67c89881825c43a9a197c45449c3a86e,
title = "Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial",
abstract = "BACKGROUND. We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS. We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was ≥12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS. IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95{\%} CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or ≥65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS. A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies.",
keywords = "Case-control studies, Insulin-like growth factor binding proteins, Insulin-like growth factors, Prostatic hyperplasia",
author = "Neuhouser, {Marian L.} and Jeannette Schenk and Yoon, {Ju Song} and Tangen, {Catherine M.} and Goodman, {Phyllis J.} and Michael Pollak and Penson, {David F.} and Thompson, {Ian M.} and Kristal, {Alan R.}",
year = "2008",
month = "9",
day = "15",
doi = "10.1002/pros.20819",
language = "English (US)",
volume = "68",
pages = "1477--1486",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "13",

}

TY - JOUR

T1 - Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial

AU - Neuhouser, Marian L.

AU - Schenk, Jeannette

AU - Yoon, Ju Song

AU - Tangen, Catherine M.

AU - Goodman, Phyllis J.

AU - Pollak, Michael

AU - Penson, David F.

AU - Thompson, Ian M.

AU - Kristal, Alan R.

PY - 2008/9/15

Y1 - 2008/9/15

N2 - BACKGROUND. We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS. We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was ≥12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS. IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or ≥65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS. A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies.

AB - BACKGROUND. We investigated whether peptides involved in cellular proliferation and apoptosis, [insulin-like growth factor I (IGFI) and its major binding protein (insulin-like growth factor binding protein 3)], predicted risk of benign prostate hyperplasia (BPH). METHODS. We conducted a nested-case-control study in the placebo arm of the prostate cancer prevention trial (PCPT). Cases (n = 727) were men with surgical or medical treatment for BPH; two or more IPSS scores >14; or two scores of at least five points over baseline one of which was ≥12. Controls (n = 727) were frequency matched by age to cases, reported no BPH treatment, and no IPSS score >8. Cases and controls remained on the PCPT placebo and were followed closely until their 7-year PCPT anniversary. Baseline serum was analyzed for IGFI and IGFBP3. Unconditional logistic regression and polytomous regression estimated the multivariate-adjusted odds ratio (OR) for BPH risk. RESULTS. IGFBP3 was inversely and the IGFI:IGFBP3 ratio was positively associated with BPH risk, but findings were statistically significant only for men with severe symptoms (OR = 0.60, 95% CI = 0.40-0.90 for the fifth vs. first quintile of IGFBP3, P-trend = 0.01). Associations did not differ by age (<65 or ≥65 years), and there was a suggestion that the IGFI:IGFBP3 - BPH risk association may be stronger among overweight men. CONCLUSIONS. A high IGFI:IGFBP3 ratio was associated with increased BPH risk, and high serum IGFBP3 was associated with decreased BPH risk among men with severe symptoms. These results confirm findings from other recent studies.

KW - Case-control studies

KW - Insulin-like growth factor binding proteins

KW - Insulin-like growth factors

KW - Prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=50949085355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949085355&partnerID=8YFLogxK

U2 - 10.1002/pros.20819

DO - 10.1002/pros.20819

M3 - Article

C2 - 18618736

AN - SCOPUS:50949085355

VL - 68

SP - 1477

EP - 1486

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 13

ER -